Title

The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series)

Document Type

Article

Publication Date

5-8-2020

Publication Title

Oral oncology

Abstract

Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid neoplasm. However, it is one of the most aggressive forms of malignancy accounting for approximately 50% of mortality associated with all thyroid cancers. Here we report two cases of ATC treated with immune checkpoint inhibitors. Next generation sequencing identified BRAFV600E mutation in one of the patients who also derived benefit from BRAF targeted therapy. We here discuss these cases highlighting the importance of expert pathological review, utilizing molecular testing to identify the underlying genetic targets for personalized therapy, and the potential role of PD-1 inhibitors for the treatment of ATC.

PubMed ID

32402656

ePublication

ePub ahead of print

First Page

104744

Last Page

104744

Share

COinS